Establishing prognostic models for intrahepatic cholangiocarcinoma based on immune cells

Table 1 Correlation between baseline characteristics and overall survival in patients with intrahepatic cholangiocarcinoma

Patient characteristic	1-year survival	1-year death	P value	3-year survival	3-year death	P value
Age
> 53 years	63	8	0.237	31	40	0.335
< 53 years	58	13		25	45
Sex
Male	80	16	0.388	35	61	0.248
Female	40	5		21	24
HBV
Yes	54	12	0.304	27	39	0.786
No	66	9		29	46
Smoking
Yes	28	5	11	9	24	0.095
No	92	16		47	61
Drinking
Yes	31	5	0.844	10	26	0.09
No	89	16		46	59
Family history
Yes	11	3	0.4391	4	10	0.369
No	109	18		52	75
WBC
Abnormal	22	5	0.5541	10	17	0.752
Normal	98	16		46	68
ALT
Abnormal	38	10	0.155	20	28	0.734
Normal	82	11		36	57
AST
Abnormal	39	12	0.03	18	33	0.419
Normal	81	9		38	52
AFP
> 400 μg/L	12	2	11	7	7	0.407
< 400 μg/L	108	19		49	78
CEA
Abnormal	22	4	11	9	17	0.556
Normal	98	17		47	68
CA199
Abnormal	57	11	0.68	24	44	0.3
Normal	63	10		32	41
Child-Pugh
Group A	62	18	0.004	56	80	0.002
Group B	58	3		0	15
Tumor necrosis
Yes	49	17	0.001	29	63	0.077
No	71	4		27	32
Tumor metastasis
Yes	58	17	0.006	47	69	0.112
No	62	4		9	26

¹Fisher test.

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; AFP: Alpha-fetoprotein; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 199; HBV: Hepatitis B virus.

Table 2 Cox regression analysis for factors affecting the 1-year survival of intrahepatic cholangiocarcinoma in 141 patients enrolled in cohorts

Variable	No. of participants (n = 141)	Univariate analysis HR (95%CI)	P value	Multivariate analysis HR (95%CI)	P value
AST			0.002		0.002
Normal	81	0.20 (0.07, 0.56)		0.18 (0.06, 0.53)
Abnormal	60	1		1
Child-Pugh			< 0.001		< 0.001
Group A	136	1		1
Group B	5	9.35 (2.74, 31.94)		68.29 (9.34, 499.16)
CD20			0.009		< 0.001
High	5	1		1
Low	136	0.19 (0.06, 0.64)		0.08 (0.02, 0.29)
Paired adjacent tissues CD20			0.08		-
High	90	1
Low	51	2.14 (0.91, 5.03)
CD4			0.14		-
High	65	1
Low	76	0.52 (0.21, 1.24)
Paired adjacent tissues CD4			0.39		0.05
High	75	1		1
Low	66	0.68 (0.28, 1.65)		0.39 (0.16, 0.98)
CD8			0.29		-
High	94	1
Low	47	1.59 (0.67, 3.78)
Paired adjacent tissues CD8			0.46		0.002
High	37	1		1
Low	104	7.75 (1.04, 57.78)		57.49 (4.44, 744.84)
CK			0.23		-
High	16	0.51 (0.17, 1.53)
Low	125	1
Paired adjacent tissues CK			0.07		-
High	133	1
Low	8	3.06 (0.90, 10.40)
CD68			0.12		-
High	9	0.38 (0.11, 1.29)
Low	132	1
Paired adjacent tissues CD68			0.10		-
High	52	0.49 (0.21, 1.15)
Low	89	1

AST: Aspartate aminotransferase.

Table 3 Cox regression analysis for factors affecting the 3-year survival of intrahepatic cholangiocarcinoma in 141 patients enrolled in cohorts

Variable	No. of participants (n = 141)	Univariate analysis HR (95%CI)	P value	Multivariate analysis HR (95%CI)	P value
Tumor necrosis			0.01		0.03
0	50	1		1
0.5	6	1.31 (1.03, 1.62)		1.26 (1.13, 1.41)
1	85	1.93 (1.20, 3.12)		1.73 (1.06, 2.84)
Tumor metastasis			< 0.001		0.008
No	20	1		0.47 (0.27, 0.82)
Yes	121	2.53 (1.48, 4.32)		1
Child-Pugh			0.001		< 0.001
Group A	136	1		0.17 (0.07, 0.46)
Group B	5	4.49 (1.80, 11.22)		1
CD20			0.03		-
High	61	1
Low	80	1.65 (1.06, 2.58)
Paired adjacent tissues CD20			0.74		-
High	83	1
Low	58	1.48 (0.96, 2.26)
CD4			0.09		-
High	16	1
Low	125	2.04 (0.89, 4.69)
Paired adjacent tissues CD4			0.15		0.02
High	100	1		2.01 (1.13, 3.57)
Low	41	0.70 (0.43, 1.14)		1
CD8			0.16		-
High	73	1
Low	68	1.35 (0.88, 2.07)
Paired adjacent tissues CD8			0.01		< 0.001
High	84	1		0.4 (0.25, 0.67)
Low	57	1.75 (1.15, 2.68)		1
CK			0.01		0.04
High	112	1		0.58 (0.35, 0.96)
Low	29	1.86 (1.15, 3.02)		1
Paired adjacent tissues CK			0.16		-
High	104	1
Low	37	1.39 (0.88, 2.19)
CD68			0.30		-
High	113	1
Low	28	0.74 (0.42, 1.31)
Paired adjacent tissues CD68			0.35		-
High	130	1
Low	11	0.65 (0.26, 1.60)

0: No necrosis; 0.5: Partial necrosis; 1: Large or complete necrosis.